A method used to measure the concentration of the peptide proBNP. Used to diagnose heart failure and to monitor the effect of treatment in patients with heart failure.
Licenced to Roche Diagnostics GmbH in 1999.
The method is currently used in more than 120 countries. The income from the licence agreement has provided tens of millions in research funding.
The test was invented by Christian Hall, MD, while he was conducting research at the Research Institute for Internal Medicine at Oslo University Hospital, Rikshospitalet.